Application of Dexmedetomidine in Cardiopulmonary Bypass Prefilling

The purpose of this study was to explore the application of dexmedetomidine (Dex) in cardiopulmonary bypass.

A total of 60 patients undergoing elective cardiopulmonary bypass were divided into control (C) group and Dex group. In the Dex group, appropriate amount of Dex was added into the membrane lung prefilling solution before anesthesia induction, while those in control group were given normal saline. The levels of mean arterial pressure (MAP) and heart rate (HR) at different times were measured. The levels of cardiac troponin I (CTNI), malondialdehyde (MDA), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) at different points (T0/T1/T2/T3/T4) in both groups were measured by enzyme-linked immunosorbent assay kits.

The intraoperative and postoperative levels of MAP and HR in the 2 groups were significantly lower than those preoperatively (P < .05). The levels of MAP and HR in the Dex group were significantly lower than those of the C group (P < .05). The levels of CTNI/MDA/IL-6/TNF-α at different points in both groups were significantly higher than those at T0 (P < .05). The serum levels of CTNI, MDA, IL-6, and TNF-α in the Dex group at T1/T2/T3/T4 were significantly lower than those in the C group (P < .05). The rate of arrhythmia in the Dex group was significantly lower than that in the C group (P < .05).

Dexmedetomidine has a stable effect in cardiopulmonary priming solution.